Abstrakt

Przypisy

• 1. Alberti L., Girola A., Gilardini L., Conti A., Cattaldo S., MichelettoG., Invitti C.: Type 2 diabetes and metabolic syndrome areassociated with increased expression of 11β-hydroxysteroid dehydrogenase 1 in obese subjects. Int. J. Obes., 2007; 31: 1826-1831
  Google Scholar
• 2. Ashraf M.S., Vongpatanasin W.: Estrogen and hypertension.Curr. Hypertens. Rep., 2006; 8: 368-376
  Google Scholar
• 3. Barlassina C., Lanzani C., Manunta P., Bianchi G.: Genetics of essentialhypertension: from families to genes. J. Am. Soc. Nephrol.,2002; 13 (Suppl. 3): S155-S164
  Google Scholar
• 4. Campino C., Carvajal C.A., Cornejo J., San Martín B., Olivieri O.,Guidi G., Faccini G., Pasini F., Sateler J., Baudrand R., Mosso L., OwenG.I., Kalergis A.M., Padilla O., Fardella C.E.: 11β-hydroxysteroid dehydrogenasetype-2 and type-1 (11β-HSD2 and 11β-HSD1) and5β-reductase activities in the pathogenia of essential hypertension.Endocrine, 2010; 37: 106-114
  Google Scholar
• 5. Campino C., Quinteros H., Owen G.I., Carvajal C.A., MoralesM., Olivieri O., Guidi G., Faccini G., Pasini F., Baudrand R., PadillaO., Valdivia C., Thichauer J., Lagos C.F., Kalergis A.M., et al.:11β-hydroxysteroid dehydrogenase type 2 polymorphisms andactivity in a Chilean essential hypertensive and normotensivecohort. Am. J. Hypertens., 2012; 25: 597-603
  Google Scholar
• 6. Carretero O.A., Oparil S.: Essential hypertension. Part I: definitionand etiology. Circulation, 2000; 101: 329-335
  Google Scholar
• 7. Chang K.J., Sung M.J., Pant A.: Effects of life stress on serumcorticol and lipid concentrations in college students. FASEB J.,2008; 22: 1091.10
  Google Scholar
• 8. Chapman K., Holmes M., Seckl J.: 11β-hydroxysteroid dehydrogenases:intracellular gate-keepers of tissue glucocorticoidaction. Physiol. Rev., 2013; 93: 1139-1206
  Google Scholar
• 9. Draper N., Walker E.A., Bujalska I.J., Tomlinson J.W., ChalderS.M., Arlt W., Lavery G.G., Bedendo O., Ray D.W., Laing I., MalunowiczE., White P.C., Hewison M., Mason P.J., Connell J.M., et al.:Mutations in the genes encoding 11β-hydroxysteroid dehydrogenasetype 1 and hexose-6-phosphate dehydrogenase interact tocause cortisone reductase deficiency. Nat. Genet., 2003; 34: 434-439
  Google Scholar
• 10. Dube S., Norby B.J., Pattan V., Carter R.E., Basu A., Basu R.:11β-hydroxysteroid dehydrogenase types 1 and 2 activity in subcutaneousadipose tissue in humans: implications in obesity anddiabetes. J. Clin. Endocrinol. Metab., 2015; 100: E70-E76
  Google Scholar
• 11. Fraser R., Ingram M.C., Anderson N.H., Morrison C., DaviesE., Connell J.M.: Cortisol effects on body mass, blood pressure,and cholesterol in the general population. Hypertension, 1999;33: 1364-1368
  Google Scholar
• 12. Gelernter-Yaniv L., Feng N., Sebring N.G., Hochberg Z., YanovskiJ.A.: Associations between a polymorphism in the 11 betahydroxysteroid dehydrogenase type I gene and body composition.Int. J. Obes. Relat. Metab. Disord., 2003; 27: 983-986
  Google Scholar
• 13. Igho Pemu P., Ofili E.: Hypertension in women: part I. J. Clin.Hypertens., 2008; 10: 406-410
  Google Scholar
• 14. Kannel W.B.: Blood pressure as a cardiovascular risk factor:prevention and treatment. JAMA, 1996; 275: 1571-1576
  Google Scholar
• 15. Kearney P.M., Whelton M., Reynolds K., Muntner P., WheltonP.K., He J.: Global burden of hypertension: analysis of worldwidedata. Lancet, 2005; 365: 217-223
  Google Scholar
• 16. Kearney P.M., Whelton M., Reynolds K., Whelton P.K., He J.:Worldwide prevalence of hypertension: a systematic review. J.Hypertens., 2004; 22: 11-19
  Google Scholar
• 17. Kosicka K., Główka F.K., Kośla A., Cymerys M., Chuchracki M.:Glucocorticoids action in etiology of hypertension. Arterial Hypertension.,2010; 14: 208-215
  Google Scholar
• 18. Krzysztoszek J., Koligat D., Ratajczak P., Bryl W., Cymerys M.,Hoffmann K., Wierzejska E., Kleka P.: Economic aspects of hypertensiontreatment in Poland. Arch. Med. Sci., 2014; 10: 607-617
  Google Scholar
• 19. Ku Y.H., Koo B.K., Kwak S.H., Cho Y.M., Shin H.D., Lee H.K., KimY., Choi J.W., Oh B., Park K.S.: Regulatory effect of common promoterpolymorphisms on the expression of the 11β-hydroxysteroiddehydrogenase type 1 gene. Horm. Res., 2009; 72: 25-32
  Google Scholar
• 20. Luft F.C.: Twins in cardiovascular genetic research. Hypertension,2001; 37: 350-356
  Google Scholar
• 21. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J.,Abbott R., Godwin J., Dyer A., Stamler J.: Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in bloodpressure: prospective observational studies corrected for the regressiondilution bias. Lancet, 1990; 335: 765-774
  Google Scholar
• 22. Rosano G.M., Vitale C., Marazzi G., Volterrani M.: Menopauseand cardiovascular disease: the evidence. Climacteric, 2007; 10(Suppl. 1): 19-24
  Google Scholar
• 23. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., LaveryG.G., Cooper M.S., Hewison M., Stewart P.M.: 11β-hydroxysteroiddehydrogenase type 1: a tissue-specific regulator of glucocorticoidresponse. Endocr. Rev., 2004; 25: 831-866
  Google Scholar
• 24. Valsamakis G., Anwar A., Tomlinson J.W., Shackleton C.H., McTernanP.G., Chetty R., Wood P.J., Banerjee A.K., Holder G., BarnettA.H., Stewart P.M., Kumar S.: 11β-hydroxysteroid dehydrogenasetype 1 activity in lean and obese males with type 2 diabetes mellitus.J. Clin. Endocrinol. Metab., 2004; 89: 4755-4761
  Google Scholar
• 25. Walker W.G., Neaton J.D., Cutler J.A., Neuwirth R., Cohen J.D.:Renal function change in hypertensive members of the MultipleRisk Factor Intervention Trial. Racial and treatment effects. JAMA,1992; 268: 3085-3091
  Google Scholar
• 26. Wang W., Lee E.T., Fabsitz R.R., Devereux R., Best L., Welty T.K.,Howard B.V.: A longitudinal study of hypertension risk factors andtheir relation to cardiovascular disease: the Strong Heart Study.Hypertension, 2006; 47: 403-409
  Google Scholar

Pełna treść artykułu